Tryptamine Therapeutics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome,...
Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9092 0475
Fax: 61 3 8678 1269
Address:
697 Burke Road, Suite 201, Camberwell, Australia
